Pharmaceutical

The era, we are living in has experienced many advancements in the healthcare system. Curative, and life-changing gene therapies have started to promise a future free of prolonged illness, possessing an ability to treat, cure or ease the life-draining diseases. In a major event, the approval of the other gene therapy for the treatment of severe, inherited blood disorder, has hit the market. Priced at 1.58 million euros, roughly about USD 1.8 million, Zynteglo, is the second most expensive therapy in the gene therapy market after Zolgensma. Developed by Bluebird Bio, Zynteglo is authorised for patients aged 12 years and older who are tormented with beta-thalassemia...